Featured Content

H. Jack West, MD
Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)

FDA Approves Keytruda For Advanced Non-Small Cell Lung Cancer

(FDA.gov) Oct 2, 2015 - The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1.

Commentary: This is clearly an important approval, but with nivolumab already approved for squamous NSCLC and listed as a recommended...

OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

AstraZeneca Pauses Two Lung Cancer Drug Combination Trials

(Reuters) Oct 9, 2015 - AstraZeneca has temporarily halted two clinical trials combining experimental drugs to treat lung cancer, following reports of lung disease in some patients, the company said on Friday.
read article »

MSK Study Examines Cancer-Care Outcomes Among US Hospitals

(MSK/On Cancer blog) Oct 8, 2015 - A new study by MSK researchers finds that readily available, unbiased Medicare claims data may be sufficient to calculate long-term survival rates at hospitals without the need for cancer stage of individual patients.
read article »

Another NICE Backing for Merck's Keytruda in Skin Cancer

(PharmaTimes [UK]) Oct 9, 2015 - The National Institute for Health and Care Excellence has given its blessing for the use of Merck's Keytruda early on in the treatment pathway for patients with advanced skin cancer.
read article »


View ALL News »

News Story Commentary By Academic and Community Oncologists

FDA Approves Keytruda For Advanced Non-Small Cell Lung Cancer (FDA.gov)

This is clearly an important approval, but with nivolumab already approved for squamous NSCLC and listed as a recommended...posted by: H. Jack West, MD

FDA Approves Pembrolizumab for Lung Cancer (Medscape Medical News)

This approval presents an epic problem: to obtain a companion diagnostic (pembro) or not to obtain a companion...posted by: Dean Gesme, MD

ED Induced by Prostate Biopsy Likely 'Underestimated' (Medscape Medical News)

Oncologists would do well to pose more questions of the urology community concerning ED and infections arising...posted by: Dean Gesme, MD

SHIVA - A Next-Generation Trial Disappoints, Provides Insights (Medscape Medical News)

Well darn, this is a bummer. But again I am relearning that there really is no substitute for good science. What...posted by: Thomas Marsland, MD

Information Blocking Undermining ASCO's CancerLinQ Initiative (Medscape Medical News)

So this article really goes to the heart of the matter. If any attempt at healthcare reform is to succeed, the...posted by: Thomas Marsland, MD

OBR Training

Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.

OBR Job Board

Ipsen has 1 new job posted.

Dava Oncology has 1 new job posted.

Bayer has 7 jobs posted.

Seattle Genetics has 3 jobs posted.

Check out the OBR Job Board here.

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™

View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.


Symbol  %Δ
DRNA +9.60%
CLDX +9.03%
ADXS +8.11%
BCRX -9.74%
RDUS -5.40%
GALT -3.69%


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results

Date: October 23, 2015
Company: Spectrum Pharmaceuticals
Product: Evomela™ (melphalan hydrochloride) for injection

Date: October 24, 2015
Company: Merrimack Pharmaceuticals / Baxalta Inc.
Product: MM-398 (irinotecan liposome injection), also known as "nal-IRI"

Date: October 27, 2015
Company: Amgen / Onyx
Product: talimogene laherparepvec (T-Vec)

See All OBR Radar items»